Siemens Healthineers AG

Feb 18–19, 2021

European Commission cleared the Siemens Healthineers / Varian merger subject to remedies, removing a major regulatory hurdle to closing the deal [7]. Removal of the regulatory overhang converted the Varian transaction from conditional to likely, shifting investor perception from "speculative acquisition" to "strategic expansion into oncology." Breakout / uptrend as deal risk materially reduced [7].

Apr 15, 2021

Siemens Healthineers completed the acquisition of Varian; Varian was established as a new reporting segment and contributed roughly €591m revenue and €98m adjusted EBIT in the partial quarter after closing [3], [4]. Market framing shifted to a transformational growth story—company now a major oncology player—while analysts flagged near-term earnings noise from purchase-price accounting, transaction and integration costs. Rally with higher volatility (M&A-driven breakout, then short consolidation) [3], [4].

Jul 30, 2021 (Q3 FY2021)

Q3 FY2021 delivered very strong results—comparable revenue growth ~38.9%, Diagnostics revenue doubled (rapid COVID-19 antigen sales ≈€600m), adjusted EBIT doubled; outlook for FY2021 was raised [4]. Short-term narrative became "COVID-driven growth surge + strategic M&A"; investors celebrated cash flow and margin strength but noted the non‑recurring nature of antigen revenues. Strong rally / breakout on outsized beat and raised guidance [4].

Late 2021 (FY2021 close)

FY2021 reporting and annual report documented the Varian integration, related purchase-price allocation/amortization and a capital increase used in part to finance the acquisition; reporting structure moved to four segments (Imaging, Diagnostics, Varian, Advanced Therapies) [8], [4]. Longer-term view: strategic portfolio diversification into cancer care accepted, but near-term EPS and goodwill/PPA effects kept valuation multiples under review. Range / consolidation while the market digested structural change and one‑off accounting impacts [8].

H1–H2 2022 (summer–autumn 2022)

Growth momentum cooled as rapid antigen-test revenue declined and China lockdowns / supply disruptions hit volumes; Q3 2022 earnings fell and management adjusted some divisional assumptions while broadly confirming FY2022 outlook [18]. Perception shifted from pandemic-fueled growth to a more mixed story—core medtech demand stable but COVID tailwind fading; investors became focused on organic growth, margins and operational execution. Drawdown / range as the COVID revenue cliff and supply issues were re-priced [18].

Nov 9, 2022

Siemens Healthineers announced a restructuring/transformation of its Diagnostics (laboratory) business to simplify the portfolio and capture ~€300m annual savings from 2025 (with one-off costs to implement) and lowered medium‑term lab targets [23]. Market treated the move as management action to restore profitability after COVID swings—shifting the narrative toward cost discipline and margin recovery, but with short-term cost recognition. Short-term volatility (drawdown on initial reaction), then stabilization as the plan provided a credible path to improved margins [23].

2023 (mid‑2023)

Operational headwinds at Varian (delivery delays, integration execution) weighed on short-term profitability; management repeatedly confirmed full‑year outlook despite the noise [19], [20]. Investors became more cautious — the strategic thesis remained intact (oncology exposure) but was tempered by execution risk; valuation drivers moved back toward evidence of sustainable orders, margins and cash flow. Volatile range / intermittent drawdowns tied to Varian execution headlines [19], [20].

Nov 6, 2024

Fiscal‑year 2024 results met the company's revenue and profit targets; Imaging and the U.S. cancer-treatment business Varian showed robust Q4 performance, prompting an ~8% jump in the share price on the day [24]. Confidence returned—market narrative rotated toward recovery and execution, with Varian seen as rebounding and the group re‑establishing its compounder credentials. Breakout / rally on confirmation of targets and visible Varian recovery [24].

Feb 6, 2025 (Q1 FY2025)

Q1 FY2025: strong start — equipment book‑to‑bill 1.21, comparable revenue growth ~5.7%, Varian comparable growth ~6.2%, group adjusted EBIT margin ~15.0%, free cash flow markedly improved; FY2025 outlook confirmed [25]. Investors increasingly view Healthineers as regaining steady organic growth and margin improvement, with Diagnostics transformation showing early benefit and Varian contributing predictable growth. Uptrend / accumulation as improving fundamentals were baked into the valuation [25].

Jul 30, 2025

Following a strong quarter and favorable macro/ tariff developments, management grew more optimistic and adjusted guidance (raised adjusted EPS midpoint and lifted parts of the revenue/margin outlook) [22], [25]. Sentiment rotated more bullish as execution and macro tailwinds reduced earlier execution/market concerns; narrative moved toward resumed multi‑year growth with margin expansion. Rally / breakout on upgraded guidance and improved visibility [22], [25].

Mid‑2026 (as of 2026‑07‑11)

SHL.XETRA trading at 34.59. Recent reported results and prior-year execution (Varian recovery, Diagnostics transformation, Imaging strength) remain the operational backdrop [24], [25]. Market perception in mid‑2026 is of a diversified med‑tech compounder: steady imaging and oncology franchises, diagnostics in structural transition; investors balance growth prospects with remaining legacy PPA/earnings noise and execution watchpoints. Range / sideways consolidation with a modest upward bias after earlier rallies (market digesting multi‑year transformation while awaiting continued margin leverage) [24], [25].